Fetal Cardiology in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES FOR FETAL ECHOCARDIOGRAPHY (Referral Indications):

• Pregnancies with a family history of CHD (recurrence risk 2–5% for one affected sibling; 10–15% if an affected parent)

• Abnormal obstetric screening ultrasound (nuchal translucency >3.5 mm, abnormal 4-chamber or outflow tract views on anomaly scan)

• Fetal arrhythmia detected on Doppler or CTG

• Maternal conditions: pre-gestational diabetes mellitus (CHD risk 3–5×), systemic lupus erythematosus (anti-Ro/La antibodies — risk of complete heart block), phenylketonuria (PKU), rubella infection in first trimester

• Teratogen exposure: isotretinoin, lithium, anticonvulsants (valproate, carbamazepine), selective serotonin reuptake inhibitors

• Fetal chromosomal anomalies: trisomy 21, 18, 13; Turner syndrome (45,X); 22q11.2 deletion (DiGeorge syndrome)

• Hydrops fetalis of any aetiology

• Monochorionic twin pregnancies (twin-to-twin transfusion syndrome — TTTS)

• In vitro fertilisation (IVF) pregnancies

• CANDIDATES FOR IN-UTERO CARDIAC INTERVENTION (Highly Selective Criteria):

• Severe fetal aortic stenosis with evolving HLHS: gestational age 22–30 weeks, viable fetus, no major extracardiac anomalies, favourable cardiac Z-scores (aortic valve annulus Z-score > −3.5 for BAV candidacy per Boston/UCSF criteria)

• Pulmonary atresia/intact ventricular septum (PA-IVS) with RV-dependent coronary circulation absent: fetal pulmonary balloon valvuloplasty at 26–32 weeks

• Intact/highly restrictive atrial septum in HLHS: fetal atrial septoplasty/stent placement to prevent left atrial hypertension and pulmonary vascular disease

• Fetal complete heart block (anti-Ro/La antibody mediated, 2°–3°): transplacental dexamethasone, hydroxychloroquine; if hydrops present — fetal cardiac pacing (select centres)

• Fetal SVT/atrial flutter causing hydrops: transplacental digoxin, flecainide, sotalol or amiodarone

• REQUIRED DIAGNOSTIC WORKUP PRIOR TO ANY INTERVENTION:

• Comprehensive fetal echocardiogram: 2D, M-mode, pulsed-wave and colour Doppler, tissue Doppler, 4D-STIC

• Fetal MRI (cardiac and brain) where appropriate

• Fetal karyotype or chromosomal microarray (CVS or amniocentesis)

• Maternal anti-Ro, anti-La, ANA, anti-dsDNA antibodies (if heart block or cardiomyopathy)

• TORCH serology and viral PCR (CMV, rubella)

• Genetic panel for Noonan syndrome (PTPN11), Alagille, CHARGE, VACTERL when syndromic CHD suspected

• Full maternal assessment: blood group and crossmatch, coagulation profile, anaesthetic risk stratification

• CONTRAINDICATIONS TO IN-UTERO INTERVENTION:

• Major extracardiac structural anomalies with poor prognosis

• Unfavourable fetal lie or placental position precluding safe needle access

• Severe fetal compromise or hydrops at presentation (relative contraindication)

• Gestational age <20 or >34 weeks (centre-specific thresholds)

• Maternal refusal or inability to provide informed consent

• Non-immune hydrops due to chromosomal lethal anomaly

CATEGORY 1 — SURVEILLANCE & MEDICAL MANAGEMENT (Non-Interventional)

Serial fetal echocardiography every 2–4 weeks to monitor lesion progression, ventricular growth, and haemodynamic impact is the baseline strategy for most prenatally detected CHDs. For fetal arrhythmias, transplacental pharmacotherapy is the standard:

• Supraventricular tachycardia (SVT) and atrial flutter: First-line — oral digoxin (maternal dosing titrated to therapeutic serum levels); Second-line — flecainide (Class Ic, highly effective for SVT with hydrops, crosses placenta efficiently); Third-line — sotalol (Class III, preferred for atrial flutter), amiodarone (reserved for refractory cases given fetal thyroid toxicity risk)

• Complete heart block (CHB): Fluorinated corticosteroids (dexamethasone 4 mg/day) may slow progression from 2° to 3° CHB if initiated early; hydroxychloroquine reduces recurrence risk in subsequent pregnancies

• Fetal cardiac failure / hydrops from structural disease: Transplacental digoxin for ventricular dysfunction; fetal thoracocentesis or amnioreduction for associated effusions

CATEGORY 2 — IN-UTERO PERCUTANEOUS CARDIAC INTERVENTIONS (Advanced / Minimally Invasive)

These procedures are performed under combined maternal regional (spinal/epidural) and fetal intramuscular anaesthesia/analgesia (fentanyl + pancuronium or vecuronium injected into the fetal thigh or intracardiacally). Ultrasound-guided, a needle is advanced transabdominally into the fetal cardiac chamber under continuous real-time echocardiographic visualisation:

1. Fetal Balloon Aortic Valvuloplasty (BAV): Target — severe aortic stenosis with evolving HLHS. A 19-gauge trocar needle enters the left ventricle; a 0.014-inch coronary guidewire is passed across the stenotic aortic valve; a low-profile coronary angioplasty balloon (typically 3–6 mm diameter, sized to 80–100% of aortic valve annulus diameter) is inflated 1–3 times. Success is defined as post-procedure antegrade flow across the aortic valve on Doppler. Published biventricular conversion rates: 30–40% (Boston Children's data).

2. Fetal Pulmonary Balloon Valvuloplasty: Target — PA-IVS with RV-independent coronary circulation. Technique mirrors BAV but needle traverses the right ventricle and pulmonary valve. Goal is RV decompression to stimulate tricuspid and RV growth.

3. Fetal Atrial Septoplasty / Atrial Stent Placement: Target — highly restrictive or intact atrial septum in HLHS. Balloon dilation of the fossa ovalis is performed; in centres with the capability, a 4–5 mm coronary stent may be deployed across the atrial septum to maintain patency and decompress the left atrium, reducing pulmonary vascular remodelling before Norwood palliation.

CATEGORY 3 — PLANNED / OPTIMISED NEONATAL CARDIAC INTERVENTIONS (Post-Delivery)

For the majority of prenatally diagnosed CHDs, in-utero intervention is not indicated; instead, prenatal diagnosis enables delivery planning at a cardiac centre for prompt neonatal intervention:

• Prostaglandin E1 (alprostadil) infusion: Immediate initiation at birth for all ductal-dependent lesions (HLHS, critical AS, critical PS, coarctation of the aorta, interrupted aortic arch, pulmonary atresia, TGA)

• Balloon Atrial Septostomy (Rashkind Procedure): Catheter-based; performed in catheterisation lab or at the bedside under echo guidance within hours of birth for TGA with restrictive atrial septum

• Neonatal open-heart surgery under cardiopulmonary bypass (CPB): Arterial Switch Operation (ASO/Jatene) for TGA — gold-standard corrective surgery in the first 2 weeks of life; total correction of ToF (patch closure of VSD + right ventricular outflow tract reconstruction); primary VSD/ASD closure; aortic arch reconstruction for interrupted aortic arch or coarctation

• Norwood Stage I Palliation: For HLHS — construction of a neo-aorta from the main pulmonary artery, atrial septectomy, and placement of a modified Blalock-Taussig-Thomas shunt (mBTT) or right-ventricle-to-pulmonary-artery conduit (Sano modification); followed by Glenn bidirectional cavopulmonary anastomosis at 4–6 months and Fontan completion at 2–4 years

• Hybrid Palliation (for HLHS): Minimally invasive alternative to Norwood — bilateral pulmonary artery banding + ductal stenting via catheter, avoiding neonatal CPB; favoured for high-risk neonates

• Radiofrequency Ablation (RFA): For postnatal refractory SVT in neonates/infants

• Advanced technologies: 3D-printed cardiac models for surgical planning; intraoperative transesophageal echocardiography; near-infrared spectroscopy (NIRS) cerebral oximetry during CPB; antegrade cerebral perfusion for neonatal arch reconstruction

PHASE 1 — PRE-ARRIVAL & TELECONSULTATION (Weeks 1–2)

• GAF Healthcare case manager collects all obstetric records, fetal echo reports, anomaly scan images, genetic results, and maternal history

• Remote second-opinion teleconsultation with the destination fetal cardiologist and maternal-fetal medicine (MFM) specialist within 48–72 hours

• Lesion-specific management plan formulated: surveillance only vs. in-utero intervention vs. planned delivery at cardiac centre

• Visa and travel logistics initiated (e-Medical Visa for India; visit/tourist visa or NOC for UAE)

• Gestational age window confirmed — timing of travel must align with the therapeutic window (typically 22–32 weeks for in-utero intervention; last trimester for delivery planning)

PHASE 2 — ARRIVAL & BASELINE ASSESSMENT (Days 1–3)

• Airport pickup by GAF-coordinated team with wheelchair assistance if needed

• Accommodation arranged adjacent to the hospital for the patient's partner/attendant

• Comprehensive in-person fetal echocardiogram (4D-STIC, colour Doppler) performed by the fetal cardiologist

• Maternal assessment: obstetric examination, blood work, anaesthetic pre-assessment if intervention planned

• Fetal cardiac board (MDT) meeting: fetal cardiologist, MFM specialist, paediatric cardiac surgeon, neonatal intensivist, cardiac anaesthesiologist, genetic counsellor — joint management decision confirmed

• Detailed informed consent obtained; patient education session with clinical coordinator and translator

PHASE 3A — IN-UTERO INTERVENTION (if indicated; Day 4–7)

• Pre-procedure tocolysis (indomethacin or nifedipine) initiated 12–24 hours prior to prevent preterm labour

• Maternal spinal or epidural anaesthesia; fetal intramuscular anaesthesia administered under ultrasound guidance (fentanyl 10 mcg/kg estimated fetal weight + pancuronium 0.3 mg/kg)

• Procedure duration: 45–90 minutes under continuous real-time echocardiographic guidance

• Immediate post-procedure assessment: fetal heart rate, cardiac function, pericardial effusion surveillance

• 24-hour inpatient fetal monitoring; CTG surveillance

• Serial fetal echocardiograms at 48 hours, 1 week, and 2 weeks post-procedure to assess haemodynamic response

• If successful and fetal/maternal status stable: decision on continued local surveillance vs. return home with close follow-up plan

• Fit-to-fly assessment: typically 2–4 weeks post-intervention if no complications (no preterm labour, stable fetal haemodynamics, no maternal morbidity)

PHASE 3B — PLANNED DELIVERY & NEONATAL INTERVENTION (if primary strategy)

• Mother admitted to the cardiac centre's high-risk obstetrics unit at 37–39 weeks (or earlier if clinically indicated)

• Delivery mode planned by the MFM team: vaginal delivery is appropriate for most CHDs; Caesarean section if obstetric or fetal indications exist

• Neonatal resuscitation team (paediatric cardiologist, neonatal intensivist, cardiac anaesthesiologist) present at delivery

• Immediate newborn assessment, prostaglandin E1 infusion if ductal-dependent lesion confirmed

• Catheter intervention (BAS, balloon valvuloplasty) or surgical correction within hours to days as per lesion-specific protocol

• NICU/PICU stay: typically 10–21 days for post-surgical recovery

• Stepdown to ward once extubated and haemodynamically stable; feeding established

PHASE 4 — DISCHARGE & FIT-TO-FLY CLEARANCE

• Discharge criteria: stable oxygen saturation on room air (or defined home oxygen levels if single-ventricle palliation), adequate oral feeding, wound healed, no signs of infection or arrhythmia

• Fit-to-fly assessment by the paediatric cardiologist: typically 6–8 weeks post neonatal open-heart surgery; 4–6 weeks post catheter-only intervention

• Commercial air travel consideration: pressurised cabin SpO2 equivalent to 15% FiO2 at sea level — neonates with cyanotic residua require supplemental oxygen clearance

• GAF Healthcare provides a comprehensive medical summary in English plus the destination country's language, digital echo and imaging files, medication list, and emergency contact numbers

• Follow-up teleconsultation scheduled at 4 weeks and 3 months post-discharge